Company profile: Normax Biomed
1.1 - Company Overview
Company description
- Provider of mRNA vaccine R&D and manufacturing for infectious diseases such as tuberculosis and HIV. Delivers Vax Factory, a modular solution for rapid, scalable production; leads the mRNA UCV Consortium; and runs GOAL 2050 to end TB and HIV transmission via mRNA vaccines, affordable treatments, and education, supporting the SDG for good health & well being.
Products and services
- GOAL 2050: An mRNA-driven initiative aiming to end Tuberculosis and HIV transmission by 2050 using mRNA vaccines, affordable treatments, and education campaigns, coordinating actions toward SDG good health and well-being
- MRNA Vaccines: Normax Biomed engineers vaccines targeting infectious diseases such as Tuberculosis and HIV, utilizing advanced mRNA technology for large-scale production supporting the SDG for good health and well-being
- Vax Factory: A modular manufacturing system architected by Normax Biomed for producing mRNA vaccines, facilitating rapid and scalable vaccine production to accelerate output.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Normax Biomed
Amicrobe
HQ: United States
Website
- Description: Provider of advanced biomaterials to prevent and treat infections, offering Amicidin-α Surgical gel for clean and clean-contaminated surgical procedures; Amicidin-β Solution for contaminated and infected tissues with tissue cleansing and microbicidal activity; Amicidin-α PFC for military prolonged field settings (up to 72 hours); and Amicidin-β/EF for emergency settings, including trauma and emergency cesarean delivery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amicrobe company profile →
GNA Biosolutions
HQ: Germany
Website
- Description: Provider of molecular diagnostic technology using Pulse Controlled Amplification to combine ultrafast nucleic acid amplification with intrinsic sample preparation, enabling solutions for laboratory, on-site and point-of-care testing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GNA Biosolutions company profile →
Revelation Biosciences
HQ: United States
Website
- Description: Provider of immunologic therapeutics and diagnostics, including Gemini, a proprietary PHAD formulation for systemic administration for prevention of post-surgical infection, acute kidney injury, and chronic kidney disease; GEM-AKI and GEM-CKD therapies that redirect the innate immune response; and GEM-SSI for prevention or treatment of healthcare-associated bacterial infections (post-surgical/post-burn, UTIs, sepsis, antibiotic-resistant).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Revelation Biosciences company profile →
Venatorx Pharmaceuticals
HQ: United States
Website
- Description: Provider of anti-infective therapies for multi-drug-resistant bacterial and viral infections, including cefepime-taniborbactam for complicated urinary tract infections and potentially hospital-acquired and ventilator-associated bacterial pneumonia; ceftibuten-ledaborbactam etzadroxil for drug-resistant Enterobacterales; and a PBP inhibitor program developing non-beta-lactam molecules.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Venatorx Pharmaceuticals company profile →
Epixis
HQ: France
Website
- Description: Provider of advanced immuno-therapy development based on recombinant virus-like particles against hepatitis C, based in Paris, France.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Epixis company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Normax Biomed
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Normax Biomed
2.2 - Growth funds investing in similar companies to Normax Biomed
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Normax Biomed
4.2 - Public trading comparable groups for Normax Biomed
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →